Ingevity Co. (NYSE:NGVT) Shares Bought by Amundi

Amundi increased its holdings in Ingevity Co. (NYSE:NGVT - Free Report) by 193.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,876 shares of the company's stock after acquiring an additional 13,097 shares during the quarter. Amundi owned approximately 0.05% of Ingevity worth $750,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Vestcor Inc purchased a new stake in Ingevity in the third quarter worth about $796,000. Geode Capital Management LLC lifted its position in shares of Ingevity by 4.3% during the third quarter. Geode Capital Management LLC now owns 815,661 shares of the company's stock valued at $31,817,000 after buying an additional 33,973 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Ingevity by 24.9% during the third quarter. JPMorgan Chase & Co. now owns 117,581 shares of the company's stock valued at $4,586,000 after buying an additional 23,460 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Ingevity during the fourth quarter valued at about $239,000. Finally, Proficio Capital Partners LLC purchased a new stake in shares of Ingevity during the fourth quarter valued at about $863,000. 91.59% of the stock is owned by hedge funds and other institutional investors.

Ingevity Stock Down 2.0 %

Shares of NGVT traded down $0.88 during mid-day trading on Friday, hitting $42.26. 514,466 shares of the company traded hands, compared to its average volume of 256,372. Ingevity Co. has a 1-year low of $30.90 and a 1-year high of $56.30. The company has a quick ratio of 1.04, a current ratio of 1.87 and a debt-to-equity ratio of 6.86. The company has a market capitalization of $1.54 billion, a PE ratio of -3.57 and a beta of 1.53. The business has a 50 day moving average of $45.28 and a 200 day moving average of $42.31.

Remove Ads

Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.66. Ingevity had a negative net margin of 30.60% and a positive return on equity of 41.44%. The firm had revenue of $298.80 million for the quarter, compared to the consensus estimate of $297.40 million. Equities research analysts anticipate that Ingevity Co. will post 4.45 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on NGVT. StockNews.com raised shares of Ingevity from a "hold" rating to a "buy" rating in a research report on Thursday, February 20th. BMO Capital Markets raised shares of Ingevity from a "market perform" rating to an "outperform" rating and increased their price target for the company from $62.00 to $65.00 in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Ingevity currently has an average rating of "Moderate Buy" and an average target price of $55.17.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.